Clinical application of a new warfarin-dosing regimen based on the CYP2C9 and VKORC1 genotypes in atrial fibrillation patients.

Jiang, Nian-Xin; Ge, Jun-Wei; Xian, Yu-Qiong; Huang, Shao-Ying; Li, Yan-Song

Jiang, Nian-Xin; Ge, Jun-Wei; Xian, Yu-Qiong; Huang, Shao-Ying; Li, Yan-Song.

Afiliação

Jiang NX; Department of Cardiology, Shanghai Seventh People's Hospital, Shanghai 200137, P.R. China.
Ge JW; Department of Cardiology, Shanghai Seventh People's Hospital, Shanghai 200137, P.R. China.
Xian YQ; Department of Cardiology, Shanghai Seventh People's Hospital, Shanghai 200137, P.R. China.
Huang SY; Department of Cardiology, Shanghai Seventh People's Hospital, Shanghai 200137, P.R. China.
Li YS; Department of Cardiology, Shanghai Seventh People's Hospital, Shanghai 200137, P.R. China.

Biomed Rep ; 4(4): 453-458, 2016 Apr.

Article em En | MEDLINE | ID: mdl-27073631

Palavras-chave

atrial fibrillation; cytochrome P450 2C9; single nucleotide polymorphisms; vitamin K epoxide reductase complex 1; warfarin

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Biomed Rep Ano de publicação: 2016 Tipo de documento: Article País de publicação: Reino Unido

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google